The Medicines and Healthcare products Regulatory Agency (MHRA) has reported a fall in the number of suspected adverse drug reactions (ADRs) reported to the Yellow Card Scheme in 2018 from key reporter groups including pharmacists, GPs and hospital doctors. Further information on the Yellow Card Scheme can be found in our Quick Reference Guide and Advice for Pharmacists document.
Since its inception in 1964, the Yellow Card Scheme has helped to identify numerous important safety issues through the reporting of ADRs on medicines and medical devices.
While the reporting of suspected ADRs is voluntary, RPS encourages, as a matter of best practice, the reporting of suspected ADRs under the Yellow Card Scheme. Anyone can report a Yellow Card including any healthcare professional or member of the public.
RPS Chief Scientist, Prof Gino Martini, encourages all pharmacists to participate in this important process of safeguarding patient safety.